A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
224actual
Sites
57
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-06 | actual | When the study began enrolling |
| Primary completion | 2025-10-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-16 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Interventions
- Drug: Amlitelimab
- Drug: Placebo
- Biological: Tdap vaccine
- Biological: PPS vaccine
Primary outcome
what the primary-completion date above is the date OFPercentage of participants with a positive tetanus response at Week 16
measured Week 16
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed